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Abstract
Objectives: Investigate the ergogenic effect of inhaling up to 1600 µg of salbutamol on intermittent running 
performance in pre-fatigued soccer players. 
Methods: In a single blind randomised repeated measures design seven male and six female soccer players 
volunteered to participant. All participants were regularly playing competitive soccer and had no history of asthma. 
Following familiarisation sessions participants visited the exercise physiology laboratory on three occasions to 
complete an intermittent running protocol followed by twelve 17.5 m sprints. Prior to each trial participants inhaled 
either: placebo, 800 µg inhaled salbutamol (SAL800) or 1600 µg inhaled salbutamol (SAL1600). Following completion 
of the sprints a sample from the first urine passed was analysed for salbutamol concentration. A repeated measures 
ANOVA was used to compare the mean sprint time, maximal sprint power, peak blood lactate post sprints and post 
sprint salbutamol urine concentration between conditions. 
Results: Mean sprint time, maximum power, maximum velocity, peak HR and peak blood lactate during the 17.5 
m sprints were not significantly different between treatments in soccer players. There was no significant difference 
between male and female players in urine drug concentration following SAL800 (mean + SD; 201.47 + 294.47 ng.ml-1 
vs. 180.2 + 102.15 ng.ml-1) or SAL1600 (739.24 + 549.21 ng.ml-1 vs. 879.58 + 633.14 ng.ml-1). Three players urine drug 
concentrations were above the WADA decision limit set at 1200 ng.ml-1. 
Conclusions: Inhaling up to 1600 µg inhaled salbutamol did not significantly improve repeated sprint performance. 
However, inhalation of 1600 µg may result in a urine concentration above the current WADA upper limit and decision 
limit leading to a positive test. Athletes should ensure they use inhaled salbutamol at therapeutic doses to avoid the 
risk of breaching the WADA decision limit. 
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Introduction
Between 2002 and 2010, International Olympic Committee (IOC) 
established the requirement that athletes present evidence of current 
asthma or exercise induced bronchoconstriction (EIB) through the 
Therapeutic Use Exemption (TUE) process. The weight of evidence 
supports the improved health care of athletes following the introduction 
of the TUE [1,2]. In contrast, there is limited evidence to suggest 
inhaled doses of β2-agonist have significant ergogenic effects according 
to a study by Pluim et al. The current List of banned substances and 
methods allows athletes to inhale up to 1600 μg salbutamol without the 
requirement of a TUE [3].
To date, there are no published studies examining the impact of 
inhaled short acting β2-agonists on team game performance. Whilst 
athletes are usually prescribed 200 - 400 μg of inhaled salbutamol, our 
experience suggests that athletes are often instructed to take salbutamol 
on an ‘as needed basis’ that could be interpreted as an ability to inhale 
an unlimited amount of salbutamol to combat respiratory symptoms. 
Given the global importance of team games such as Soccer it is 
imperative that the performance impact of inhaled short acting β2-
agonists be examined to justify their position on the WADA list of 
prohibited substances.  
The purpose of this study was to examine the ergogenic effect of 
inhaling 800 µg and 1600 µg of salbutamol versus placebo repeated 
sprint performance in pre-fatigued soccer players. Furthermore, to 
investigate the impact of prior exercise and gender on urine salbutamol 
concentrations following inhalation of the WADA recommended 
upper limit of 1600 µg of Salbutamol. 
Materials and Method
Ethical approval for this study was provided by the Liverpool John 
Moores University Local Ethics Committee (ethics no: 09E18GW). 
Seven male (mean + SD; age 23.1 + 3.9 years; weight 72.9 + 4.3 kg; 
height 177.0 + 4.7 cm) and six female (21.3 + 1.4 years; weight 63.9 + 
5.8 kg; height 162.3 + 4.7 cm) soccer players volunteered and provided 
written and verbal informed consent. All players played regular 
competitive 11 a-side soccer at least once a week and trained specifically 
for soccer at least twice a week. All participants were free from asthma 
and EIB. This was confirmed by the presentation of a negative Eucapnic 
Voluntary Hyperpnoea challenge [4]. On three separate occasions 
players were required to complete a 52 minute intermittent running 
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protocol followed by twelve, 17.5 m sprints. Each trial was completed 
in a temperate environment (18°C and 40% relative humidity). Each 
trial was separated by 7 days. Fifteen minutes prior to the initiation of 
each intermittent run players inhaled one of the following treatments, 
via a pocket chamber, in a randomised single blind design: 
Treatment 1: 16 inhalations of placebo (PLA)
Treatment 2: 8 inhalations of 100 µg salbutamol, 8 inhalation of 
placebo (SAL800)
Treatment 3: 16 inhalations of 100 µg salbutamol (SAL1600)
Maximal flow volume loops were recorded at baseline, 10 minutes 
post-treatment inhalation and 5 minutes post-simulated soccer match. 
A 90 ml urine sample was obtained between 30 and 180 minutes 
following the cessation of the twelve 17.5 m sprints.
The intermittent running protocol involved players completing 52 
minutes of an adapted version of a validated soccer game performance 
treadmill test [5,6]. The test was conducted on a motorised treadmill 
(Pulsar, h/p/cosmos, Germany). The players were asked to complete 
five LOW and two HIGH intensity stages (Figure 1). The female low 
and high intensity stages were 10% slower than the male speeds. The 
stages were completed in the following order LOW, LOW, HIGH, 
LOW, LOW, HIGH, LOW. Between each stage there was a one minute 
stationary period (Figure 1).
Fifteen minutes following the soccer specific intermittent running 
protocol participants completed twelve 17.5 m sprints with a 10 s 
recovery between each sprint. This test is an adaption of the Repeated 
Anaerobic Sprint Test (RAST), which involves 6×35 m sprints [7]. The 
players completed the 17.5 m sprints on a non-motorised treadmill 
(Force Treadmill System, Woodway, SA). For each sprint the following 
variables were recorded: time, peak power and peak velocity. HR was 
monitored during the sprints and peak HR across all the twelve sprints 
was recorded. Consistent verbal encouragement was given to the 
players during each sprint. Players were encouraged to complete the 
sprints as fast as they could. 
Three maximal flow-volume loops were measured at baseline, 
ten minutes after inhalation of PLA, SAL800 and SAL1600, and five 
minutes after the soccer specific intermittent running protocol. On 
each occasion maximal flow volumes were measured according to the 
European Respiratory Society (ERS) criteria [8].
Prior to the commencement of each trial players were asked to 
provide a urine sample in order to void them of urine, after which the 
placebo or salbutamol was administered as described above. Players 
were instructed to collect the first sample of urine passed following 
completion of the laboratory-based tests in line with in-competition 
anti-doping procedures as outlined in the World Anti-Doping Code 
International Standard for Testing [9]. Consumption of water during 
this period was encouraged ad libitum to ensure diuresis. From the 
sample provided by each subject a 20 ml aliquot of urine was stored at 
-80°C until analysis.
All urinalysis was performed at HFL Sport Science (Fordham, 
UK) an independent drug surveillance laboratory and former WADA-
accredited laboratory. Sample preparation involved the addition of 200 
ng of Salbutamol-D3 (NMI) as an internal standard to 1 ml of urine. 
Following the addition of 2 ml of 0.1M phosphate buffer pH 6.8 and 
100 μl of E. Coli enzyme (β-glucuronidase) solution the mixture was 
incubated overnight at 37°C. Strata XC 60 mg solid phase extraction 
cartridges (Phenomenex, Macclesfield, UK) were conditioned with 3 
ml of methanol followed by 3 ml of reagent grade water. Following 
centrifugation at 3500 rpm for 5 min the samples were applied to the 
cartridges. The cartridges were then washed with 3 ml of 0.1M acetate 
buffer pH 9.0 followed by 3 ml of reagent grade water, 3 ml of 0.1M 
HCl, 3 ml of methanol and 3 ml of diethyl ether. The cartridges were 
then dried for 5 min for vacuum and samples were eluted into glass 
vials with two, 1 ml of basic drug elution solvent (160 ml ethyl acetate, 
34 ml propan-2-ol and 6 ml 34% ammonia solution). Samples were 
then evaporated to dryness at ambient temperature using a centrifugal 
vacuum concentrator (Genevac Ltd, Ipswich, UK) and reconstituted in 
10 μl of isopropanol followed by 200 μl of basic reconstitution solution 
(495 ml of 0.1 acetic acid mixed with 5 ml Benzyldimethylphenyl 
Ammonium). Samples were centrifuged at 3000 rpm for 10 min prior 
to LCMS submission. Samples were injected onto a Thermo Scientific 
Accela HPLC system coupled to a Thermo Scientific LTQ Orbitrap 
Discovery Mass Spectrometer (Thermo Fisher Scientific, Waltham, 
USA). Chromatographic separation was performed on a Waters 
Atlantis T3 column (2.1×100 mm, particle size 3 µm; Waters Ltd, 
Elstree, UK) at 35°C. The mobile phase was a gradient system of 0.1% 
acetic acid aqueous solution containing uracil (300 ng.ml-1) and 0.1% 
acetic acid in acetonitrile containing uracil (300 ng.ml-1) set at a flow 
rate of 0.4 ml.min-1. 
The urine salbutamol concentrations reported correspond to the 
sum of the free and glucuronide conjugates. The samples were analysed 
over the calibration range of 10-2000 ng.ml-1. Samples with salbutamol 
concentrations greater than the upper limit of quantification were 
diluted with blank human urine prior to analysis. The lower limit of 
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quantification was accepted as the lowest standard on the calibration 
curve (10 ng.ml-1).
Male and female data were analysed together. Mean sprint time 
to complete the twelve, 17.5 m sprints under each of the treatments 
was analysed by a repeated measures ANOVA. Similar analyses were 
undertaken for peak power, peak velocity and peak HR. Repeated 
measures ANOVA were used to compare FEV1, FVC, PEF and FEF25-
75. A p value of <0.05 was deemed significant for all analysis.
Results
All seven male and six female players completed the football specific 
run and twelve, 17.5 m sprints under each condition. No participant 
reported any adverse symptoms from inhaling either 800 or 1600 µg 
salbutamol.Under each of the three treatments no significant difference 
was observed in mean sprint time (PLA 4.74+0.65s; SAL800 4.65+0.55 
s; SAL1600 4.74+0.53 s; p=0.35), peak power (PLA 1641.7+492.0 W; 
SAL800 1681.7+524.0 W; SAL1600 1738.8+499.9 W; p=0.40), peak 
velocity (PLA 4.99+0.66 m.s-1; SAL800 5.00+0.70 m.s-1; SAL1600 
5.01+0.68 m.s-1; p=0.51), peak HR (PLA 182.6+5.1 b.min-1; SAL800 
184.6+4.5 b.min-1; SL1600 183.4+4.54 b.min-1; p=0.22) or, peak lactate 
(PLA 11.55+2.16 mmol.l-1; SAL800 12.45+2.59 mmol.l-1; 13.52+2.3 
mmol.l-1; p=0.06).
Maximal lung function did not significantly alter between 
treatments at baseline, 10 minutes after inhalation of treatment or 5 
minutes after the completion of the football specific run.
Following inhalation of 800 μg and 1600 μg of salbutamol and 
completion of a football-specific running protocol and twelve, 17.5 m 
sprints under temperate (20°C, 40% RH) ambient conditions the cohort 
reported mean (± SD) urine drug concentrations of 250.91 + 234.51 
ng.ml-1 and 804.02 + 568.46 ng.ml-1, respectively (see figure 2). Whilst 
mean (+ SD) urine drug concentrations following inhalation of 800 
μg of salbutamol was 301.47 + 294.47 ng.ml-1 in males compared to 
180.12 + 102.15 ng.ml-1 in females there was no significant difference 
according to sex (Figure 2). Likewise, there were no significant sex 
differences in urine drug concentrations following inhalation of 1600 
μg of salbutamol in male 739.24 + 549.21 ng.ml-1 and female 879.58 + 
633.14 ng.ml-1 players. Nevertheless there was a high degree of inter-
individual differences in urine drug concentrations amongst male and 
female participants. Whilst mean urine drug concentrations did not 
breach the WADA urinary threshold for salbutamol two male and 
three female players recorded urine drug concentrations that exceeded 
the threshold (1000 ng.ml-1), of which, three cases were above the 
WADA decision limit set at 1200 ng.ml-1.
Discussion
The results from the current study suggest that inhaling up to 1600 
µg of salbutamol does not result in an improvement in repeated sprint 
performance in pre-fatigued soccer players. Despite this, our results 
demonstrate that it is possible for athletes to present with a salbutamol 
urine concentration above 1000 ng.ml-1 following inhalation of up to 
1600 µg of salbutamol.
Previous studies focused on inhaled salbutamol have generally 
employed non-specific performance trials such as running to 
exhaustion or physiological markers of performance [10]. Few of the 
previous studies have demonstrated any improvement following the 
inhalation of acute doses of up to 800 µg Salbutamol on running time 
to exhaustion, O2max, peak power, 20 km cycling time-trial and total 
work during a 30 s Wingate test [10].  Dickinson et al. [11] reported 
no improvement in 5 km running time trial performance following 
inhalation of 1600 µg salbutamol. Elers et al. [12] suggested inhaling 
an acute dose of up to 4000 µg salbutamol resulted in no improvement 
in cycling time to exhaustion or oxygen kinetics. Accordingly, from 
a performance perspective the current WADA guidelines permitting 
athletes to inhale up to 1600 µg in a single day appear appropriate as 
there is no resultant improvement in performance in non-asthmatic 
athletes. Furthermore, there also appears to be no improvement in 
strength, power or endurance when none asthmatic athletes inhale 1600 
µg Salbutamol on a daily basis for 6 weeks [13]. However, in contrast to 
our findings a recent study has suggest there may be an improvement 
in swimming sprint performance and maximal contraction of the 
quadriceps femoris if inhaled salbutamol is taken in combination with 
inhaled long acting β2-agonists [14]. In addition, oral salbutamol taken 
acutely and over a two week period has been shown to improve peak 
power output on repeated cycling sprint performance [15]. However, 
Hostrup et al. [15] did report β2-adrenergic stimulation was blunted 
in the second and third sprints. In our study we used a soccer specific 
running protocol to induce fatigue in our participants prior to the 
17.5 m sprints. It may be possible that the preceding soccer specific 
treadmill run impacted on the potential for inhaled salbutamol to 
improve individual sprint and repeated sprint performance. Future 
studies investigating repeated sprint performance may benefit from 
inhaling salbutamol directly before the sprinting protocol. 
The current WADA regulations impose a urinary salbutamol 
threshold of 1000 ng.ml-1for salbutamol [3]. This regulation is to 
distinguish legitimate therapeutic use from misuse. Supporting such 
a threshold are maximal dosing recommendations of 1600 μg per day 
Figure 2: (a) Mean (+ SD) and (b) Individual urine SAL concentration (ng.ml-1) post repeated 17.5 m sprints in temperate (20oC, 40% RH) environment following 
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[3]. However, whilst the recommended dosing regimen is between 100 
and 400 μg up to four times daily, salbutamol is typically prescribed 
pro re nata (‘when required’). Individuals encouraged to administer 
salbutamol pro re nata may inhale doses of salbutamol over and above 
such recommendations for therapeutic purposes, either intentionally or 
inadvertently. In such cases athletes are at risk of exceeding the WADA 
threshold and in doing so, facing possible anti-doping sanctions. 
Previous research has attempted to examine the excretion of 
salbutamol administered by different routes including oral and inhaled 
[16,17] and across a range of acute doses from 200 μg and 800 μg [18] 
and repeated doses over several hours [19]. The current study is the first 
to examine the urinary excretion of an acute, high dose in comparison 
with an intermediate dose following intermittent running in soccer 
players. Whilst the findings did not suggest any differences according 
to gender there was a large variation between individuals at the various 
doses. This large inter-subject variation confirmed the likelihood that 
individuals inhaling acute, high doses of salbutamol may exceed the 
current WADA urinary threshold of 1000 ng.ml-1. Indeed the current 
study also demonstrates that following such a dosing regimen may result 
in urine salbutamol levels in excess of 1200 ng.ml-1. This concentration 
is significant since it represents a level referred to by WADA as the 
‘Decision Limit, above which a sample would be classified as an adverse 
analytical finding (AAF) [9] and warrant further investigation.    
The maximal recommended dosing regimen for salbutamol clearly 
acts as an upper limit for those requiring immediate relief of asthma 
symptoms. Individuals who regularly use high doses of salbutamol or 
exceed these recommendations clearly demonstrate poor management 
of their condition. There lies the problem from an anti-doping 
regulatory perspective when the evidence to support ergogenic 
properties is not present and the likelihood of poor control of asthma 
and EIB are high. From a sports medicine perspective improved care 
may constitute better diagnosis, management and education amongst 
athletes. Regardless of whether salbutamol is on or off the WADA list 
of banned substances team medical officers must follow best practice in 
the diagnosis of respiratory conditions such as EIB prior to providing 
inhalers for therapeutic use [20].
Conclusion
Our findings suggest there is no ergogenic benefit, from inhaling 
up to 1600 µg of salbutamol, on intermittent running performance in 
soccer players. However, inhalation of 1600 µg may result in a urine 
concentration above the current WADA upper limit and decision 
limit leading to a positive test finding. Athletes should ensure they use 
inhaled salbutamol at therapeutic doses to avoid the risk of breaching 
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